Last reviewed · How we verify
COPPER OXODOTREOTIDE CU-64
At a glance
| Generic name | COPPER OXODOTREOTIDE CU-64 |
|---|---|
| Modality | Recombinant protein |
| Phase | FDA-approved |
| First approval | 2020 |
Approved indications
Common side effects
Key clinical trials
- Using Novel Imaging to More Safely Treat Neuroendocrine Tumors (PHASE1)
- NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer. (PHASE1)
- Combination External Radiation and PRRT for Large GI Neuroendocrine Tumors. (PHASE1)
- Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With GEP-NETs and PPGLs (PHASE2)
- Surgical Debulking Prior to Peptide Receptor Radionuclide Therapy in Well Differentiated Gastroenteropancreatic Neuroendocrine Tumors (PHASE4)
- Clinical Application of Somatostatin Receptor and Norepinephrine Transporter Targeted Imaging for Diagnosis and Staging of Neuroblastoma and Pheochromocytoma/Paraganglioma
- Randomized Interval Assessment Trial of Lu177-Dotatate in Slowly Progressive G1-2 Advanced Midgut Neuroendocrine Tumors (PHASE3)
- 64Cu-DOTATATE PET-CT-skanning and Infective Endocarditis. (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- COPPER OXODOTREOTIDE CU-64 CI brief — competitive landscape report
- COPPER OXODOTREOTIDE CU-64 updates RSS · CI watch RSS